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Background: Alzheimer’s disease (AD) is a multifactorial disorder characterized by the
progressive deterioration of neuronal networks. The clearance of Aβ from the brain and
anti-inflammation are potential important strategies to prevent and treat disease. In a
previous study, we demonstrated the grape seed extract (GSE) could reduce brain Aβ
burden and microglia activation, but which polyphenol plays a major role in these events
is not known. Here, we tested pharmacological effects of (−)epicatechin, one principle
polyphenol compound in GSE, on transgenic AD mice.
Methods: APP/PS1 transgenic mice were fed with (−)epicatechin diet (40 mg/kg/day) and
curcumin diet (47 mg/kg/day) at 3 months of age for 9 months, the function of liver, Aβ levels
in the brain and serum, AD-type neuropathology, plasma levels of inflammatory cytokines
were measured.
Results:Toward the end of the experiment, we found long-term feeding of (−)epicatechin
diet was well tolerated without fatality, changes in food consumption, body weight, or
liver function. (−)Epicatechin significantly reduced total Aβ in brain and serum by 39 and
40%, respectively, compared with control diet. Microgliosis and astrocytosis in the brain
of Alzheimer’s mice were also reduced by 38 and 35%, respectively. The (−)epicatechin
diet did not alter learning and memory behaviors in AD mice.
Conclusion: This study has provided evidence on the beneficial role of (−)epicatechin
in ameliorating amyloid-induced AD-like pathology in AD mice, but the impact of
( )epicatechin on tau pathology is not clear, also the mechanism needs further research.−
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder that
primarily strikes the elderly. Clinically, AD patients develop symp-
toms consisting of a gradual loss of memory, mental confusion,
language disturbances, personality and behavioral changes, and
diminished abilities for reasoning, orientation, and judgment.
According to the widely accepted “amyloid hypothesis” (1), the
overproduction of Aβ in the brain, or failure of Aβ clearance lead
to brain deposition of Aβ and a series of secondary pathological
events, such as neurofibrillary tangle formation, neuronal dysfunc-
tion, and microglia activation, which characterize affected brain
of AD (2, 3).
Aβ is regarded to play pivotal or causal roles in the development
of AD, therapeutic strategies have been mainly focused on reduc-
ing Aβ production, inhibiting Aβ deposition, and promoting Aβ
clearance (4). Accumulation of Aβ in the brain and development
of AD have been linked to dietary factors. Polyphenols are a type
Abbreviations: FA, formic acid; HPLC, high-performance liquid chromatography;
IFN-γ, interferon-γ; IL-1, interleukin-1; PCR, polymerase chain reaction; SDS,
sodium dodecyl sulfate; TBS, tris buffered saline; TNF-α, tumor necrosis factor
alpha.
of antioxidants presenting in plant-based foods and confer signif-
icant health benefits, including protection against AD and other
memory problems (5, 6).
Our previous studies have shown that polyphenols in the grape
seed extract (GSE) could prevent the Aβ deposition and attenu-
ates the inflammation in the brain of a transgenic mouse mode
(7). GSE, which contains various polyphenols including gallic
acid, catechin, EGCG, EGC, epicatechin-3-gallate, epicatechin, and
proanthocyanidins (8), but which polyphenol plays a role in AD
pathology is not clear. As (−)epicatechin is one of a major com-
ponent of polyphenols from GSE (7, 9), we investigate whether
(−)epicatechin is effective in AD treatment. Here, we report the
beneficial effects of (−)epicatechin diet consumption on the neu-
rodegenerative process of AD mice. Meanwhile, curcumin was
used as a positive control, which can clean Aβdeposition and
ameliorate inflammation in brain of AD mice (7).
MATERIALS AND METHODS
ANIMALS
APP/PS1 transgenic mice were provided by Jackson Laboratories.
These mice were constructed on a C57BL/6 background and bear a
chimeric mouse/human (Mo/Hu) APP695 with mutations linked
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to familial AD (KM 593/594 NL) and human PS1 carrying the
exon-9-deleted variant associated with familial AD (PS1dE9) in
one locus under control of a brain- and neuron-specific murine
Thy-1 promoter element (10). They were bred in standard ani-
mal house (at approximately 8 weeks of age, male C57BL/6 mice
and female APP/PS1 mice breeding pairs, or female C57BL/6
mice and male APP/PS1 mice were housed together as breed-
ing pairs). Genotypes were determined by PCR following the
provider’s instruction. Mice were housed individually in standard
cages with a reversed 12-h day/night cycle and provided commer-
cial pellet diet and water ad libitum. And then, we got enough
number of animals for the research.
At the age of 3 months, APP/PS1 mice were divided into three
diet groups, (−)epicatechin group (N = 12, half males and half
females, fed with (−)epicatechin diet), curcumin group (N = 12,
half males and half females, fed with curcumin diet) and normal
diet group (N = 12, half males and half females, fed with normal
diet). Another age and sex matched wild-type littermates (N = 12,
half males and half females, fed with normal diet) were used as a
control group.
All the animals were treated in strict compliance with the United
States Public Health Service Policy on Human Care and Use of Lab-
oratory Animals, the National Institutes of Health Guide for the
Care and Use of Laboratory Animals, and the Guidelines for the
Care and Use Laboratory Animals of the Kunming Medical Uni-
versity. The study had been approved by the Committee for Animal
Experiments and Ethics at the Kunming Medical University.
DIETARY INTERVENTION
All experimental diets were prepared by Zoopery Centre, Kunming
Medical University. The control diet was the standard commercial
pelleted diet (Beijing KeaoXieli Feed Company, Beijing, China).
The groups of transgenic mice treated with (−)epicatechin and
curcumin (>95% purity by HPLC, Shanghai Tauto Biotech Co.,
Ltd.), respectively received doses of 40 and 47 mg/kg/day based on
previous reports (11,12). The animals were fed with the above diets
for 9 months starting 3 months age, when no Aβ plaque deposition
is detectable in the brain. Food consumption and body weight data
were collected every 3 months throughout the study.
MORRIS WATER-MAZE TEST
After 9 months of dietary treatment, a Morris water-maze test was
used to analyze memory capability of these mice. In brief, the appa-
ratus consisted of a circular water tank (100 cm in diameter and
40 cm in height, filled with water in a depth of 30 cm, at 21± 1°C)
with a platform (11 cm in diameter) set under the water (1 cm
below the water surface). The mice must learn to escape from water
and step onto the platform. In this study, the mice were trained
seven consecutive days with three trials per day. For each trial, each
animal was put into the water at one of three starting positions of
non-platform quadrants, respectively, and allowed at most 60 s free
swim. The escape latency (test duration), path length (total dis-
tance traveled), and swim speed (average speed) will be recorded.
(If the animal finds the platform within 60 s, it should be stayed for
an additional 30 s on the platform; or, it should be gently guided
on the platform, and allowed to stay for 30 s). On day 8, a probe
trial was performed to test retention of the task. The platform was
removed and each mouse was allowed 60 s free swim at a starting
point far from the platform (starting point B). The time animal
swim in the target zone, the number of crossings over the plat-
form, and the swim track were recorded semi-automatically by
the Anymaze video tracking system (Stoelting Co., USA).
TISSUE SAMPLING AND PREPARATION
At the end of the experiment, the mice were deeply anesthetized
with the lethal concentration of inhaled ether, the blood was sam-
pled from the right atrium of the heart, and then perfused with
50 ml of normal saline, the brains were removed and bisected in
the mid-sagittal plane, Left brain hemisphere was fixed in 4%
paraformaldehyde (pH 7.4) for 24 h and incubated for 24 h in 30%
sucrose, coronal sections of the brain were cut at 35µm thickness
with a cryosectioning microtome and stored at 4°C in PBS con-
taining 40% glycol for histological quantitative analysis and the
right brain hemisphere was snap frozen in liquid nitrogen and
stored at−80°C until biochemical analysis.
AD-TYPE PATHOLOGY AND QUANTITATIVE IMAGE ANALYSIS
The left brain hemisphere was processed according to the free-
floating immunohistochemistry protocol as described previously
(13). Briefly, a series of five equally spaced tissue sections, span-
ning the entire brain were selected and stained using free-
floating immunohistochemistry for total Aβ (Biotin-conjugated
mouse anti-Aβ antibody 6E10, Serotec; 1:1000 dilution), acti-
vated microglia (rat monoclonal anti-CD45, Millipore Bioscience
Research Reagents; 1:1000 dilution), and astrocyte (rabbit poly-
clonal anti-glial fibrilliary acidic protein, Dako, Denmark; 1:1000
dilution), respectively. Sections were incubated overnight with
primary antibodies at 4°C and the reaction products were visu-
alized with diaminobenzidine (No. AB500-500 Slide Kit Chemical
International, Inc., Millipore).
The region of neocortex and hippocampus manually was
selected for quantification of total Aβ plaques, microgliosis,
astrogliosis, and microhemorrhage. All images were acquired in
the same session. Images were collected at 4×magnification using
constant bulb temperature and exposure, yielding the area fraction
of the total positive staining against the area of tissue analyzed.
Microhemorrhage (MH) staining and quantification were per-
formed with the described method: in brief, the sections were
stained with Prussian blue working solution (equal parts of freshly
made 5% potassium ferrocyanide and 5% hydrochloric acid) for
30 min at room temperature,washed in deionized water, and coun-
terstained with nuclear fast red. MH events in the form of the
number of Prussian blue-positive profiles were counted in the
brains of each mouse on all sections under microscope, and the
average number of hemosiderin deposits was calculated per each
brain hemisphere. All image analyses were processed in a blind
manner.
BIOCHEMICAL ASSAY
Quantification of Aβ peptide levels in the mouse brain and plasma
ELISA analysis of the brain Aβ was processed as described previ-
ously (14). Briefly, frozen brain was homogenized and sonicated
in TBS containing protease inhibitors. Homogenates were cen-
trifuged at 100,000 g for 1 h at 4°C, and the resultant supernatant
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was collected, representing the TBS-soluble fraction (Aβ-TBS).
The resultant pellet was suspended and sonicated in water con-
taining 2% SDS and protease inhibitors. The SDS solubilized
homogenates were centrifuged at 100,000× g for 1 h at 4°C, and
the resultant supernatant was collected, representing the SDS-
soluble fraction (Aβ-SDS). The resultant pellet was then extracted
in 70% formic acid (FA) and centrifuged, and the resultant super-
natant was collected, representing the SDS-insoluble fraction (Aβ-
FA). Before ELISA assay, formic acid extracts were neutralized
by 1:20 dilution into 1 M Tris phosphate buffer, pH11, and then
diluted in sample buffer. Concentrations of Aβ40 and Aβ42 in
brain extract and serum were quantitatively measured by ELISA
according to the manufacturer’s instructions (Cat. #EZBRAIN 40
and Cat. #EZBRAIN 42, Millipore). Using the wet weight of brain
tissue in the original homogenate, the final values of brain Aβwere
expressed as picograms per gram wet weight of brain.
Quantification of TNF-a, IL-1β, and IFN-γ in the mouse plasma
Tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β),
interleukin-6 (IL-6), and interferon-γ (IFN-γ) in the plasma
of mice were measured using ELISA kits (Cat No.BMS607/2,
BMS6002, BMS606, BMS603/2 eBioscience, USA) as per manu-
facturer’s instructions.
Assessment of toxicity of (−)epicatechin
Total bilirubin, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) were analyzed by Clinical Laboratory of
First Affiliated Hospital of Kunming Medical University.
STATISTICAL ANALYSIS
Unless otherwise stated, the data in the text and figures are
expressed as mean± SEM. Statistical comparisons between groups
were analyzed using t -test, one-way ANOVA, or two-way repeated-
measures ANOVA for testing the significance of values. If signifi-
cant, post hoc testing was done with Tukey’s HSD or Dunnett’s T3
methods, and appropriate P values are reported based on adjust-
ment according to Levene’s test for equality of the variance. All
these analyses were performed using SPSS 17.0.
RESULTS
(−)EPICATECHIN IS WELL TOLERATED IN APP/PS1 TRANSGENIC MICE
We started to feed (−)epicatechin and curcumin diet at 3 months
of age. The mean daily food consumption of the mice was 0.10–
0.12 g/g body weight, the corresponding daily (−)epicatechin
consumption was 40µg/g body weight and daily curcumin con-
sumption was 77–98µg/g body weight. The equivalent consump-
tion in a 60 kg human is about 0.14 g/day for (−)epicatechin and
0.35 g/day for curcumin, as derived using FDA criteria for convert-
ing drug equivalent dosages across species, based on body surface
area [human equivalent dose in milligrams per kilogram= animal
dose in milligrams per kilogram× (animal weight in kilograms
per human weight in kilogram)0.33](15). No difference between
APP/PS1 transgenic mice and wild-type animals was found in
animal viability, body weight, general activities (Figure 1A), daily
food consumption (Figure 1B), and liver function, which can be
reflected by the normal serum levels of bilirubin, AST, and alanine
aminotransferase aspartate (ALT) (Figure 1C, the data of bilirubin
was not shown because the level was below detection).
FIGURE 1 | (−)Epicatechin is well tolerated in APP/PS1 transgenic
mice. APP/PS1 transgenic mice were fed control, curcumin or
(−)epicatechin diets for 9 months from 3 months of age. In parallel,
wild-type littermates were fed with control diet too. (A) Body weight was
measured at 3, 6, 9, and 12 months of age. (B) Food intake was monitored
at 3, 6, 9, and 12 months of age, and was calculated as food intake (gram)
per gram body weight per day. (C) Serum indices of liver functional status
such as AST and ALT. Points and bar graphs represent group mean (±SEM).
EFFECTS OF (−)EPICATECHIN ON LEARNING AND MEMORY IN APP/PS1
TRANSGENIC MICE
After 9 months treatment, all animals received behavior test. Mice
were trained for 7 day with three trials per day to find the hidden
platform in the Morris water maze. On day 8, mice were under-
gone a probe trial in which the platform was removed and the
time to enter the correct quadrant where the platform had been
was measured (Figure 2). But acquisition of the task did not differ
between the groups (ANOVA F = 2.004, P > 0.05), (−)epicatechin
mice did not perform well on the probe trials, indicating that the
(−)epicatechin did not enhance retention of spatial memory.
(−)EPICATECHIN REDUCES Aβ LEVELS IN THE BRAIN AND SERUM AND
REDUCES AMYLOID DEPOSITION IN APP/PS1 TRANSGENIC MICE
To assess the effect of (−)epicatechin on amyloid protein levels
in the brain and the serum, the levels of both Aβ40 and 42 in
brain homogenates and serum were analyzed by specific sandwich
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ELISA. Aβ in the SDS fraction represents soluble fraction and the
diffuse Aβ plaques, and Aβ in the formic acid fraction represents
the fibrillar Aβ plaques. Total Aβ level was generated from the sum
of Aβ40 and 42 of the different fraction.
We found significant reduction in total Aβ burden in the brain
of mice consuming (−)epicatechin (P < 0.05) and curcumin diet
(P < 0.01) when comparing to Control group (ANOVA F = 8.823,
FIGURE 2 | Effect of (−)epicatechin on learning and memory in
APP/PS1 transgenic mice after treated 9 months, Mice were trained for
7 day in Morriz water maze. On the 8 day performed a probe test, and the
time to enter the correct quadrant where the platform had been was
measured. One-way ANOVA with Student–Newman–Keuls post hoc
corrections in this graph, no differences (P >0.05). Bars represent
mean±SEM. Statistical software package was SPSS17.0.
P < 0.01), (−)epicatechin and curcumin diet reduced total Aβ
burden by 39 and 51% respectively (Figure 3A). Similarly, Aβ
levels in 2% SDS extracts of (−)epicatechin and curcumin diet
groups were also reduced by 37 and 68%, respectively, and the lev-
els in the insoluble pellet in formic acid extracts were reduced by 39
and 47%, respectively (Figures 3B,C, ∗ ∗ ∗P < 0.01). The concen-
tration of total Aβ in the serum was also assayed by ELISA kit, the
Aβ level in the serum tended to be lower than that of the normal
diet control group (Figure 3D), and the data did not show signif-
icant correlation with brain total Aβ burden (Pearson r = 0.644,
P = 0.554).
Amyloid plaques on coronal sections (35µM thick) of the
neocortical and hippocampal areas were detected with immuno-
histochemical staining (by CD6E10 antibody). The numbers of
Aβ deposits were counted. Quantitative analysis showed a signifi-
cant reduction of Aβ deposits in mice consuming (−)epicatechin
(P < 0.05) and curcumin diet (P < 0.01) compared with control
diet consumption (ANOVA F = 5.310, P = 0.019) (Figure 4). The
result is in agreement with the brain Aβ levels of ELISA analy-
sis. The total Aβ plaques detected by immunohistochemistry was
reduced by 40% in the (−)epicatechin diet group and 55% in
the curcumin diet group. These results imply beneficial effects
of (−)epicatechin and curcumin, which could reduce amyloid
protein aggregation.
(−)EPICATECHIN PREVENTS AD-TYPE NEUROPATHOLOGY IN APP/PS1
TRANSGENIC MICE
The microgliosis (by CD45 antibody) and astrocytosis (using
GFAP antibody) in the neocortical and hippocampal regions
FIGURE 3 | Effects of (−)epicatechin consumption on Aβ levels in the
brain and serum of APP/PS1 transgenic mice. Aβ peptide concentration in
the brain and serum of each animal was measured using ELISA.
(A) Comparison of total Aβ, Aβ in SDS fraction (Aβ-SDS) and Aβ in formic acid
fraction (Aβ-FA) among groups. (B) Comparison of total Aβ40, Aβ40-SDS and
Aβ40-FA. (C) Comparison of total Aβ42, Aβ42-SDS and Aβ42-FA.
(D) Comparison of total Aβ, Aβ40 and Aβ42 in serum. * and ** denote
P <0.05 versus APP/PS1 transgenic mice fed with control diet.
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FIGURE 4 | Effects of (−)epicatechin diet on Aβ deposits in the brain of
the APP/PS1 transgenic mice. (A) Aβ plaques of in neocortex of APP/PS1
transgenic mice fed with control diets; (B) fed with (−)epicatechin; (C) fed
with curcumin; (D) comparison of Aβ plaque area fraction in neocortex and
hippocampus among groups. Statistical analysis showed a significant
decrease in the number of plaques in the brain treated with (−)epicatechin
and curcumin diets. P <0.05 versus APP/PS1 transgenic mice fed with
control diet. Scale bar=0.5 mm.
were investigated by immunohistochemistry. Quantitative analy-
sis followed by one-way ANOVA (F = 19.115, P < 0.001 and
F = 6.041, P < 0.05) revealed a remarkable differences in levels
of microgliosis and astrocytosis between transgenic mice fed with
(−)epicatechin diet and animals fed with control diet. The mice
consuming (−)epicatechin diet showed significant lower level
of microgliosis and astrocytosis by 38 and 35%, but no obvi-
ous microgliosis and astrocytosis were observed in the brains of
wild-type animals (Figures 5 and 6).
Microhemorrhage has been associated with increasing age (16,
17). In AD, MH have been linked with β-amyloid (Aβ) deposition
in AD and cerebral amyloid angiopathy (CAA) (18–20). Following
the previous method, we detected cerebral MH in brain sections
stained with Iron-Prussian Blue staining. After treatment with
(−)epicatechin and curcumin diets. MH tended to be lower than
transgenic mice fed with control diet, but the difference between
groups did not reach statistical significance (Dunnett T3, P > 0.05,
Figure 7).
EFFECTS OF (−)EPICATECHIN TREATMENT ON INFLAMMATION
CYTOKINES IN SERUM
Inflammation is an important hall mark in AD development.
Activated microglia mainly release a combination of both pro-
and anti-inflammatory cytokines, including IL-1(interleukin-
1), IFN-γ (interferon-γ), TNF-α(tumor necrosis factor), and
IL-6 (21). Here, we measured levels of the proinflammatory
cytokines in the serum using the ELISA Kits. Compared with
control (37.6± 12.1 pg/ml) and curcumin (30.4± 14.2 pg/ml)
diet, (−)epicatechin (11.6± 2.8 pg/ml) diet significant decreased
TNF-α level (P < 0.05) in the plasma of transgenic mice (ANOVA
TNF-α, F = 12.261, P < 0.05). No change was found in the
cytokines of IL-1and IFN-γ when comparing with control (Tg)
diet group (ANOVA IL-1, F = 1.428, P = 0.274; IFN-γ, F = 0.272.
P = 0.845; Figure 8), and the level of IL-6 in serum was too low to
be detected.
DISCUSSION
The present study suggests long-term oral (−)epicatechin as a food
additive can be effective on ameliorating AD pathology in mice.
Our results indicate that (−)epicatechin appears to be well toler-
ated in relation to viability and systemic toxicity by both wild-type
and APP/PS1 mice. No adverse event was seen in both strains
of mice. (−)Epicatechin significantly inhibited the deposits of
amyloid in the brain and reduced the levels of Aβ in the blood
and the brain. (−)Epicatechin also attenuated neuroinflamma-
tion in APP/PS1 mice, including reducing levels of microgliasis
and astrogliosis and lowering the concentration of TNF-α in the
plasma of transgenic mice. But (−)epicatechin did not improve
learning and memory in APP/PS1 mice after 9 months treatment.
This result is different from a previous report showing that the
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FIGURE 5 | Effects of (−)epicatechin diet group on microgliosis in
the brain. The area of neocortex and hippocampus was selected for
quantification of activated microglia immunostaining. (A) Microgliosis
in hippocampus and neocortex of APP/PS1 transgenic mice fed with
control diet, (B) transgenic mouse fed with curcumin, (C) transgenic
mouse fed with (−)epicatechin, (D) wild-type mouse fed with control
diet, (E) Comparison of CD45 area fraction in neocortex and
hippocampus among groups. Statistical analysis showed a significant
decrease in the number of microgliosis in the brain treated with
(−)epicatechin and curcumin diets. P <0.05 versus APP/PS1
transgenic mice fed with control diet. Scale bar=0.5 mm. Original
magnification, 4×.
consumption of (−)epicatechin increases memory function of
normal mice (22) and this difference can be ascribed to different
strains of mice, dosage, and length of treatment.
Soluble Aβ oligomers are major contributors to the toxicity
associated with the peptide. The amyloid peptides Aβ40 and 42
are thought to contribute differentially to the disease process (23).
It is found that Aβ42 is much more prone to aggregate and more
toxic to neurons than Aβ40 (24, 25). We examined Aβ levels in
the 2% SDS and formic acid by ELISA. While Aβ42 and 40 lev-
els are decreased in animals fed with (−)epicatechin relative to
untreated AD transgenic animals (Dunnett’s T3 Assay, P < 0.05),
the ratio of insoluble Aβ42/40 was significantly decreased in
(−)epicatechin diet fed mice (1.95) relative to fed standard diet
mice (2.05).
The decreased ratio (5%) of insoluble Aβ42/40 in
(−)epicatechin consumption mice may be attributable to the
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FIGURE 6 | Effects of (−)epicatechin diet group on astrogliosis in the
brain. The area of neocortex and hippocampus was selected for quantification
of astrogliosis immunostaining. (A) Astrogliosis in hippocampus and
neocortex of APP/PS1 transgenic mice fed with control, (B) transgenic mouse
fed with curcumin, (C) transgenic mouse fed with (−)epicatechin,
(D) wild-type mouse fed with control diets, (E) comparison of GFAP area
fraction in neocortex and hippocampus among groups. Statistical analysis
showed a significantly decrease in the astrogliosis in the brain treated with
(−)epicatechin and curcumin diets. P <0.05 versus APP/PS1 transgenic mice
fed with control diet. Scale bar=0.5 mm. Original magnification, 4×.
modulation of β-secretase inhibition. β-secretase is one of impor-
tant enzymes in the process of APP to Aβ42 (26). However,
significant change in the β-secretase activity as measured BACE
activity assays, suggests that β-secretase may not play a role in
Aβ reduction caused by (−)epicatechin diet. However, we can-
not rule out the possibility that the γ-secretase is involved in
Aβ metabolism in (−)epicathechin treated mice, γ-secretase is
a large multimeric membrane-bound protein composed of pre-
senilins (PS1), nicastrin, and Aph-1. Mutations in three different
genes, APP and presenilin-1 and -2 (PS1 and PS2), are known to
cause early onset familial AD (27, 28). For this reason, γ-secretase
has been considered as a plausible molecular target as a means
to interfere with the production of Aβ. Inhibiting γ-site cleav-
ages of γ-secretase is a more attractive approach, which using an
APP/Aβ-binding small molecular compound can achieve allosteric
modulation of γ-secretase activity and attenuate the Aβ42/40 ratio
(29), additional work is required to understand if (−)epicatechin
directly target the γ-secretase.
(−)Epicatechin is a flavonoid, possesses free radical scav-
enging activity and superoxide dismutase activity (30–32).
(−)Epicatechin is able to traverse the blood–brain barrier after oral
ingestion (33, 34), so it is possible that Aβ neurotoxicity be blocked
by an antioxidant mechanism, and by inhibition of Amyloid-beta
oligomers and/or fibril formation (35).
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Inflammation is considered a major pathological aspect of AD.
As a part of the inflammatory response, activated astrocytes and
microglia are characteristically found in abundance in the plaques.
Besides, AD brains show increased expression of several proin-
flammatory cytokines such as IL-6, IL-1β, and tumor necrosis
factor-α (TNF-α), which are hardly detectable in normal brains
(36–39). Increased levels of these cytokines have been described
not only in the brains but also in blood and cerebrospinal fluid
from AD patients (40).
FIGURE 7 | Effects of (−)epicatechin and curcumin consumption on
microhemorrhage profiles. Microhemorrhage events in the form of the
number of Prussian blue-positive profiles were counted, and the average
number and standard error of hemosiderin deposits was calculated per
each brain hemisphere. Comparison of microhemorrhage profiles per each
brain hemisphere among groups. *, **denote P >0.05 versus wild-type
littermate fed with Control diet.
In this study, our results showed the chronic (−)epicatechin
consumption effectively alleviated microgliosis and astrogliosis,
and reduced level of TNF-α among transgenic mice. This is con-
sistent with the fact that inhibition of TNF-α by various means
reduces AD-like pathology in transgenic AD mice (41, 42). In
addition, the levels of IL-1β and IFN-γ in serum did not change
and the level of IL-6 was too low to be detected. The data are con-
sistent with our previous studies (13), indicating (−)epicatechin
can suppress inflammation in the mouse model of AD.
Although Aβ is the initial factor of the AD pathogenesis, recent
efforts to reduce Abeta production or clear Abeta deposition in
the brain did not success in clinical trials, such as beta- or gamma-
secretase inhibitor and immunotherapies (43). The lessons learnt
from these failures suggest that an effective therapy should simul-
taneously target different aspects of AD pathogenesis, as AD is a
multifactorial disease. Neuroinflammation and oxidative stress are
key components of AD pathogenesis. Although they are secondary
to Abeta deposition, they play critical roles in promoting AD devel-
opment and progress, via increasing Abeta production, enhancing
Abeta deposition, and cause other pathological events such as tau
hyperphosphorylation, neuronal degeneration, and death. In this
regard, polyphenols possess their own advantages. So far, some
polyphenols have been suggested to be able to reduce Abeta pro-
duction, inhibit Abeta aggregation, attenuate neuroinflammation
and oxidative stress, ameliorate tau hyperphosphorylation (44–
46). Thus, polyphenols possibly represent a group of natural drug
candidate for AD.
In summary, our research confirms the efficacy of
(−)epicatechin in APP/PS1 mice AD, but the impact of
(−)epicatechin on tau pathology is not clear, also the mechanism
needs further research.
FIGURE 8 | Effects of curcumin and (−)epicatechin consumption on
plasma levels ofTNF-a, IL-1β, and IFN-γ. Levels of TNF-a, IL-1β, and
IFN-γ in serum were measured using ELISA kits (eBioscience).
Statistical analysis showed the level of TNF-α was significantly
decreased in serum of mice (Tg) treated with (−)epicatechin diet.
P <0.05 versus APP/PS1 transgenic mice fed with control diet. But
levels of IL-1β and IFN-γ did not occur any change in transgenic mice
when comparing.
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